Boehringer Ingelheim

Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale

2 weeks ago talkbio0Tagged AimedBio, Antibody-Drug Conjugates, Biopharma, Boehringer Ingelheim, Cancer Therapeutic Procedure, EyePoint, Funding, Licensing, stock sale, therapeutic autologous dendritic cells

Boehringer Ingelheim; AimedBio; antibody-drug conjugate; ADC; cancer therapy; biotech licensing deal; EyePoint Pharmaceuticals; stock sale; biopharma funding

Boehringer Ingelheim Breaks Decade-Long Drought with FDA Approval of Jascayd for Idiopathic Pulmonary Fibrosis

3 weeks ago talkbio0Tagged Approved, Boehringer Ingelheim, Chronic lung disease, Idiopathic Pulmonary Fibrosis, Jascayd, lung scarring, nerandomilast, Pulmonary Fibrosis, United States Food and Drug Administration

Boehringer Ingelheim; Jascayd; nerandomilast; FDA approval; idiopathic pulmonary fibrosis; IPF; lung scarring; first new treatment; chronic lung disease

Novartis and Boehringer Ingelheim Launch Direct-to-Consumer Drug Sales, Bypassing Middlemen

4 weeks ago talkbio0Tagged Boehringer Ingelheim, Cosentyx, Direct-to-Consumer, drug price, DTC, middlemen, Novartis, Patient access, Pharmaceutical Sales, PhRMA, Spiriva Respimat

Boehringer Ingelheim; Novartis; Direct-to-consumer (DTC); Pharmaceutical sales; Middlemen; Drug pricing; Patient access; Cosentyx; Spiriva Respimat; PhRMA

Boehringer Ingelheim breaks into oncology as FDA grants accelerated approval to Hernexeos (zongertinib) for HER2 TKD–mutated NSCLC

3 months ago talkbio0Tagged Accelerated, Approved, Beamion, Boehringer Ingelheim, competition, Confirmatory Trial, Enhertu, erbB-2 Receptor, Frequency of Responses, HER2-mutant, Hernexeos, Identifier, LUNG-1, Mutation, Non-Small Cell Lung Carcinoma, non-squamous NSCLC, Oncomine Dx Target Test, oral targeted therapy, Priority Review, Requirement, TKD, United States Food and Drug Administration, Zongertinib

Boehringer Ingelheim; Hernexeos; zongertinib; FDA approval; accelerated approval; non-squamous NSCLC; HER2 TKD mutations; Oncomine Dx Target Test; Beamion LUNG-1; objective response rate; first oral targeted therapy for HER2-mutant NSCLC; priority review; breakthrough therapy designation; confirmatory trial requirement; competition with Enhertu